BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ancker OV, Krüger M, Wehland M, Infanger M, Grimm D. Multikinase Inhibitor Treatment in Thyroid Cancer. Int J Mol Sci 2019;21:E10. [PMID: 31861373 DOI: 10.3390/ijms21010010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Sharma A, Sharma L, Nandy SK, Payal N, Yadav S, Vargas-De-La-Cruz C, Anwer MK, Khan H, Behl T, Bungau SG. Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer. Molecules 2023;28. [PMID: 36677808 DOI: 10.3390/molecules28020750] [Reference Citation Analysis]
2 Sahana J, Cortés-Sánchez JL, Sandt V, Melnik D, Corydon TJ, Schulz H, Cai Z, Evert K, Grimm D, Wehland M. Long-Term Simulation of Microgravity Induces Changes in Gene Expression in Breast Cancer Cells. Int J Mol Sci 2023;24. [PMID: 36674696 DOI: 10.3390/ijms24021181] [Reference Citation Analysis]
3 Qu N, Qu J, Huang N, Zhang K, Ye T, Shi J, Chen B, Kan C, Zhang J, Han F, Hou N, Sun X, Pan R. Calycosin induces autophagy and apoptosis via Sestrin2/AMPK/mTOR in human papillary thyroid cancer cells. Front Pharmacol 2022;13:1056687. [PMID: 36588732 DOI: 10.3389/fphar.2022.1056687] [Reference Citation Analysis]
4 Oh JM, Gangadaran P, Rajendran RL, Hong CM, Lee J, Ahn BC. Different Expression of Thyroid-Specific Proteins in Thyroid Cancer Cells between 2-Dimensional (2D) and 3-Dimensional (3D) Culture Environment. Cells 2022;11. [PMID: 36428988 DOI: 10.3390/cells11223559] [Reference Citation Analysis]
5 Li J, Zhang X, Mu Z, Sun D, Sun Y, Lin Y. Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review. Front Immunol 2022;13:943916. [DOI: 10.3389/fimmu.2022.943916] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhang X, Yan Z, Meng Z, Li N, Jia Q, Shen Y, Ji Y. Radionuclide 131I-labeled albumin-indocyanine green nanoparticles for synergistic combined radio-photothermal therapy of anaplastic thyroid cancer. Front Oncol 2022;12:889284. [DOI: 10.3389/fonc.2022.889284] [Reference Citation Analysis]
7 Gubbi S, Koch CA, Klubo-Gwiezdzinska J. Peptide Receptor Radionuclide Therapy in Thyroid Cancer. Front Endocrinol (Lausanne) 2022;13:896287. [PMID: 35712243 DOI: 10.3389/fendo.2022.896287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Yoon JH, Hong AR, Kim HK, Kang H. Lung Related Complications in Patients with Advanced Thyroid Cancer during Lenvatinib Therapy: Case Series and Literature Review. Int J Thyroidol 2022;15:42-48. [DOI: 10.11106/ijt.2022.15.1.42] [Reference Citation Analysis]
9 Rogucki M, Sidorkiewicz I, Niemira M, Dzięcioł JB, Buczyńska A, Adamska A, Siewko K, Kościuszko M, Maliszewska K, Wójcicka A, Supronik J, Szelachowska M, Reszeć J, Krętowski AJ, Popławska-kita A. Expression Profile and Diagnostic Significance of MicroRNAs in Papillary Thyroid Cancer. Cancers 2022;14:2679. [DOI: 10.3390/cancers14112679] [Reference Citation Analysis]
10 Qu N, Hui Z, Shen Z, Kan C, Hou N, Sun X, Han F. Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development. Front Endocrinol 2022;13:873027. [DOI: 10.3389/fendo.2022.873027] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Deng C, Han D, Feng M, Lv Z, Li D. Differential diagnostic value of the ResNet50, random forest, and DS ensemble models for papillary thyroid carcinoma and other thyroid nodules. J Int Med Res 2022;50:3000605221094276. [PMID: 35469474 DOI: 10.1177/03000605221094276] [Reference Citation Analysis]
12 Grimm D. Recent Advances in Thyroid Cancer Research. Int J Mol Sci 2022;23:4631. [PMID: 35563021 DOI: 10.3390/ijms23094631] [Reference Citation Analysis]
13 Mu Y, Song F, Yuan K, Zhang Z, Lu Y, Fu R, Zhou D. A Comprehensive Risk Assessment and Stratification Model of Papillary Thyroid Carcinoma Based on the Autophagy-Related LncRNAs. Front Oncol 2021;11:771556. [PMID: 35284335 DOI: 10.3389/fonc.2021.771556] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Cui Y, Liu Y, Mu L, Li Y, Wu G. Transcriptional Expressions of ALDH1A1/B1 as Independent Indicators for the Survival of Thyroid Cancer Patients. Front Oncol 2022;12:821958. [PMID: 35280765 DOI: 10.3389/fonc.2022.821958] [Reference Citation Analysis]
15 Cheng S, Wu ATH, Batiha GE, Ho C, Lee J, Lukman HY, Alorabi M, Alrasheedi AN, Chen J. Identification of DPP4/CTNNB1/MET as a Theranostic Signature of Thyroid Cancer and Evaluation of the Therapeutic Potential of Sitagliptin. Biology 2022;11:324. [DOI: 10.3390/biology11020324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Wang J, Liu H. miR-551b is Associated with the Poor Prognosis and Malignant Development of Papillary Thyroid Cancer Through Regulating ERBB4. Horm Metab Res 2022;54:113-8. [PMID: 35130572 DOI: 10.1055/a-1735-3318] [Reference Citation Analysis]
17 Asya O, Yumuşakhuylu AC, Bağcı P, Kaya H, Gönen A, Gündoğdu Y, Muradov T, Şahin A, Oysu Ç. Relationship of PPARG overexpression with prognostic parameters in papillary thyroid carcinoma. Acta Otorhinolaryngol Ital 2022;42:34-40. [DOI: 10.14639/0392-100x-n1034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang AY, Li W, Zhou HY, Chen J, Zhang LB. Identification of DNA Repair-Related Genes Predicting Clinical Outcome for Thyroid Cancer. J Oncol 2022;2022:8809469. [PMID: 35035484 DOI: 10.1155/2022/8809469] [Reference Citation Analysis]
19 刘 延. Research Progress of BRAF V600E Gene Mutation in Papillary Thyroid Carcinoma. ACM 2022;12:8499-8507. [DOI: 10.12677/acm.2022.1291227] [Reference Citation Analysis]
20 Kaae AC, Kreissl MC, Krüger M, Infanger M, Grimm D, Wehland M. Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer-Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension. Int J Mol Sci 2021;22:12217. [PMID: 34830100 DOI: 10.3390/ijms222212217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Mu R, Ma Z, Lu C, Wang H, Cheng X, Tuo B, Fan Y, Liu X, Li T. Role of succinylation modification in thyroid cancer and breast cancer. Am J Cancer Res 2021;11:4683-99. [PMID: 34765287] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Higuchi T, Igarashi K, Yamamoto N, Hayashi K, Kimura H, Miwa S, Bouvet M, Tsuchiya H, Hoffman RM. Multikinase-Inhibitor Screening in Drug-resistant Osteosarcoma Patient-derived Orthotopic Xenograft Mouse Models Identifies the Clinical Potential of Regorafenib. Cancer Genomics Proteomics 2021;18:637-43. [PMID: 34479916 DOI: 10.21873/cgp.20286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Melnik D, Krüger M, Schulz H, Kopp S, Wehland M, Bauer J, Baselet B, Vermeesen R, Baatout S, Corydon TJ, Infanger M, Grimm D. The CellBox-2 Mission to the International Space Station: Thyroid Cancer Cells in Space. Int J Mol Sci 2021;22:8777. [PMID: 34445479 DOI: 10.3390/ijms22168777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Umakanthan S, Bukelo MM. Concise genetic profile of lung carcinoma. Postgrad Med J 2021:postgradmedj-2021-139860. [PMID: 34083369 DOI: 10.1136/postgradmedj-2021-139860] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ge MH, Zhu XH, Shao YM, Wang C, Huang P, Wang Y, Jiang Y, Maimaitiyiming Y, Chen E, Yang C, Naranmandura H. Synthesis and characterization of CD133 targeted aptamer-drug conjugates for precision therapy of anaplastic thyroid cancer. Biomater Sci 2021;9:1313-24. [PMID: 33350399 DOI: 10.1039/d0bm01832e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
26 Li G, Zhang T, Huang K, Zhu Y, Xu K, Gu J, Huang S, Gu C, Zhan R, Shen J. Long noncoding RNA GAS8-AS1: A novel biomarker in human diseases. Biomed Pharmacother 2021;139:111572. [PMID: 33838502 DOI: 10.1016/j.biopha.2021.111572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Qi Y, He J, Zhang Y, Wang L, Yu Y, Yao B, Tian Z. Circular RNA hsa_circ_0001666 sponges miR‑330‑5p, miR‑193a‑5p and miR‑326, and promotes papillary thyroid carcinoma progression via upregulation of ETV4. Oncol Rep 2021;45:50. [PMID: 33760216 DOI: 10.3892/or.2021.8001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
28 Zhen J, Song Z, Su W, Zeng QC, Li J, Sun Q. Integrated analysis of RNA-binding proteins in thyroid cancer. PLoS One 2021;16:e0247836. [PMID: 33711033 DOI: 10.1371/journal.pone.0247836] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Caperton CO, Jolly LA, Massoll N, Bauer AJ, Franco AT. Development of Novel Follicular Thyroid Cancer Models Which Progress to Poorly Differentiated and Anaplastic Thyroid Cancer. Cancers (Basel) 2021;13:1094. [PMID: 33806425 DOI: 10.3390/cancers13051094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Grimm D. Cell and Molecular Biology of Thyroid Disorders 2.0. Int J Mol Sci 2021;22:1990. [PMID: 33671462 DOI: 10.3390/ijms22041990] [Reference Citation Analysis]
31 Liu Y, Zhang H, Wang H, Du J, Dong P, Liu M, Lin Y. Long non-coding RNA DUXAP8 promotes the cell proliferation, migration, and invasion of papillary thyroid carcinoma via miR-223-3p mediated regulation of CXCR4. Bioengineered 2021;12:496-506. [PMID: 33522355 DOI: 10.1080/21655979.2021.1882134] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
32 Colombo C, Giancola N, Fugazzola L. Personalized treatment for differentiated thyroid cancer: current data and new perspectives. Minerva Endocrinol (Torino) 2021;46:62-89. [PMID: 33213119 DOI: 10.23736/S2724-6507.20.03342-8] [Reference Citation Analysis]
33 Huelse JM, Fridlyand DM, Earp S, DeRyckere D, Graham DK. MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. Pharmacol Ther 2020;213:107577. [PMID: 32417270 DOI: 10.1016/j.pharmthera.2020.107577] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
34 Li L, Lin X, Xu P, Jiao Y, Fu P. LncRNA GAS5 sponges miR ‐362‐5p to promote sensitivity of thyroid cancer cells to 131 I by upregulating SMG1. IUBMB Life 2020;72:2420-31. [DOI: 10.1002/iub.2365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
35 Ramezani M, Saeidi M, Zarei A, Hasani M. Investigating the demographic characteristics and pathological manifestations of thyroid Cancer during the last two decades (1997-2017) in patients referred to Baqiyatallah hospital, Tehran, Iran. J Diabetes Metab Disord 2020;19:1165-72. [PMID: 33553021 DOI: 10.1007/s40200-020-00617-x] [Reference Citation Analysis]
36 Vrachimis A, Iakovou I, Giannoula E, Giovanella L. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of thyroid nodules and cancer. Eur J Endocrinol 2020;183:G41-8. [PMID: 32438345 DOI: 10.1530/EJE-20-0269] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]